PhoreMost

PhoreMost is a drug discovery company developing a phenotypic screening platform to identify and prosecute previously undruggable disease targets.

The platform systematically unmasks cryptic binding sites across the human proteome and links them to therapeutic functions in a live-cell context, enabling the discovery of molecular glue degraders and other targeted protein degradation modalities.

The company focuses on oncology and inflammatory disease, working with academic and pharmaceutical partners to advance novel degrader therapeutics.